1563 studies found for:    Open Studies | "Lymphatic Diseases"
Show Display Options
Rank Status Study
1 Recruiting National Lymphatic Disease and Lymphedema Registry
Condition: Lymphedema
Intervention:
2 Recruiting Study of Autoimmune Lymphoproliferative Syndrome (ALPS)
Conditions: Autoimmune Disease;   Lymphatic Disease;   Lymphoproliferative Disorder;   Canale-Smith Syndrome
Intervention:
3 Recruiting Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
Conditions: Lymphatic Diseases;   Hematopoietic Malignancy
Intervention: Biological: Umbilical Cord Blood (UCB)
4 Recruiting Characterization of the Pathogenesis of Primary and Secondary Lymphatic Disorders
Conditions: Lymphangiomatosis;   Lymphedema;   Lymphangiectasia;   Pulmonary Lymphangiectasia
Intervention:
5 Unknown  Imaging Lymphatic Function in Normal Subjects and in Persons With Lymphatic Disorders
Condition: Lymphedema
Intervention: Drug: near-infrared fluorescence imaging
6 Recruiting E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma
Condition: Peripheral T-Cell Lymphoma
Intervention: Biological: denileukin diftitox (E7777)
7 Available Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant
Conditions: Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Chronic Myeloid Leukemia;   Myelodysplastic Syndrome;   Lymphomas;   Bone Marrow Failure;   Hemoglobinopathy;   Immune Deficiency;   Osteopetrosis;   Cytopenias;   White Blood Cell Abnormalities;   Red Blood Cell Abnormalities
Intervention: Biological: CD34+ enriched, T Cell Depleted donor stem cell product
8 Recruiting A Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Intervention: Drug: Brentuximab vedotin
9 Recruiting Study Evaluating ABT-199 in Subjects With Relapsed or Refractory Non-hodgkin Lymphoma or Multiple Myeloma
Conditions: Non-Hodgkin Lymphoma;   Multiple Myeloma
Intervention: Drug: ABT-199
10 Unknown  TREatment of degeNerative and Neoplastic Diseases With Rituximab
Condition: Diffuse Large B Cell Lymphoma
Intervention: Biological: Rituximab
11 Recruiting Bronchoscopic Sampling Techniques in Sarcoidosis
Conditions: Mediastinal Lymph Node Enlargement;   Sarcoidosis;   Tuberculosis;   Lymphomas
Interventions: Procedure: EBUS guided transbronchial forceps biopsy (EBUS-TBFB);   Procedure: EBUS guided transbronchial needle aspiration (EBUS-TBNA);   Procedure: large bore (19G) histologic needle biopsy of the mediastinal lymph nodes;   Procedure: Bronchoalveolar lavage (BAL);   Procedure: Endobronchial forceps biopsy
12 Unknown  Ultrasonographic Differentiation Between Kikuchi's Disease and Lymphoma in Patients With Cervical Lymphadenopathy
Conditions: Lymphoma;   Kikuchi's Disease
Intervention:
13 Recruiting Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma
Condition: Cancer
Intervention: Drug: CUDC-427
14 Recruiting Comparing Navigation With Xperguide vs. Electromagnetic Tracking vs. Conventional Methods During Percutaneous Image Guided Procedures
Conditions: Infection;   Cancer;   Neoplasm;   Empyema;   Granuloma
Interventions: Device: Xperguide CT;   Device: Computed Tomography
15 Unknown  Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: Nipent, Cytoxan, Rituxan
16 Recruiting Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies
Conditions: Lymphoma, B-Cell;   T-Cell Lymphoma
Intervention: Drug: RP6530
17 Unknown  Autologous and Allogeneic Transplant for Relapsed Lymphoma
Conditions: Non-Hodgkin's Lymphoma;   Hodgkins Disease
Interventions: Drug: Fludarabine and Busulfan;   Drug: Fludarabine, Busulfan and ATG
18 Recruiting Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
Condition: Indolent Non-Hodgkin's Lymphomas
Interventions: Drug: Idelalisib;   Drug: Rituximab;   Drug: Placebo to match idelalisib
19 Unknown  Safety Study of Bevacizumab to Treat Women With a History of Breast Cancer and Suffering From Upper Extremity Lymphedema
Condition: Lymphedema
Intervention: Drug: Bevacizumab
20 Recruiting Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Anemia;   Fever, Sweats, and Hot Flashes;   Stage I Chronic Lymphocytic Leukemia;   Stage I Small Lymphocytic Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Small Lymphocytic Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma;   Weight Changes
Interventions: Drug: ibrutinib;   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Biological: rituximab;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years